Press Releases Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:51:10 14/01/2026 pm IST			5-day change	1st Jan Change
757.84 ^USD	-0.14%		-6.80%	-1.92%

14/01	Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs	MT
13/01	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating	MT

Press Releases

03/01	Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026	GL
31/12	Biocon And Regeneron Enter Global Settlement On Aflibercept Biosimilar	AQ
24/12	Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic	AQ
23/12	Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma	GL
23/12	Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference	GL
19/12	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030	AQ
08/12	Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment	GL
02/12	Regeneron and Tessera partner to develop gene therapy for AATD	AQ
01/12	Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)	GL
25/11	Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)	GL
25/11	Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)	AQ
20/11	Regeneron Pharmaceuticals - Libtayo Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma with High Risk of Recurrence after Surgery and Radiation	AQ
20/11	Regeneron Pharmaceuticals - EYLEA HD Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion and for Monthly Dosing Across Approved Indications	AQ
20/11	EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications	GL
19/11	Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation	GL
14/11	Regeneron Pharmaceuticals Highlights Progress at American Society of Hematology, with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs	AQ
13/11	Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs	GL
08/11	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet	GL
07/11	Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review	GL
05/11	Regeneron, The False Claims Act, And A New Era In Government Enforcement	AQ
04/11	Regeneron Announces Investor Conference Presentations	GL
03/11	Regeneron Pharmaceuticals, Inc. - Dupixent Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award	AQ
31/25/31	Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award	GL
31/25/31	Regeneron Pharmaceuticals : Q3 2025 Earnings Conference Call Transcript	PU
29/25/29	OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs

January 14, 2026 at 02:38 am IST